Back
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
JP. Gisbert, M. Romano, J. Molina-Infante, AJ. Lucendo, E. Medina, I. Modolell, M. Rodríguez-Tellez, B. Gomez, J. Barrio, M. Perona, J. Ortuño, I. Ariño, JE. Domínguez-Muñoz, Á. Perez-Aisa, F. Bermejo, JL. Domínguez, P. Almela, J. Gomez-Camarero, J. Millastre, E. Martin-Noguerol, AG. Gravina, M. Martorano, A. Miranda, A. Federico, M. Fernandez-Bermejo, T. Angueira, L. Ferrer-Barcelo, N. Fernández, AC. Marín, AG. McNicholl
Dig Liver Dis 2015 Feb;47(2):108-13.
PubMed: 25454706
Abstract
Aim was to evaluate the efficacy and tolerability of a moxifloxacin-containing second-line triple regimen in patients whose previous Helicobacter pylori eradication treatment failed. Prospective multicentre study including patients in whom a triple therapy or a non-bismuth-quadruple-therapy failed. Moxifloxacin (400mg qd), amoxicillin (1g bid), and esomeprazole (40 mg bid) were prescribed for 14 days. Eradication was confirmed by (13)C-urea-breath-test. Compliance was determined through questioning and recovery of empty medication envelopes. 250 patients were consecutively included (mean age 48 ± 15 years, 11% with ulcer). Previous (failed) therapy included: standard triple (n = 179), sequential (n = 27), and concomitant (n = 44); 97% of patients took all medications, 4 were lost to follow-up. Intention-to-treat and per-protocol eradication rates were 82.4% (95% CI, 77-87%) and 85.7% (95% CI, 81-90%). Cure rates were similar independently of diagnosis (ulcer, 77%; dyspepsia, 82%) and previous treatment (standard triple, 83%; sequential, 89%; concomitant, 77%). At multivariate analysis, only age was associated with eradication (OR = 0.957; 95% CI, 0.933-0.981). Adverse events were reported in 25.2% of patients: diarrhoea (9.6%), abdominal pain (9.6%), and nausea (9.2%). 14-day moxifloxacin-containing triple therapy is an effective and safe second-line strategy in patients whose previous standard triple therapy or non-bismuth quadruple (sequential or concomitant) therapy has failed, providing a simple alternative to bismuth quadruple regimen.
Associated compounds:
Compound Name
with link to compound page |
Structure | Number of references |
---|---|---|
Urea | 1130 |